Cardiovascular disease (CVD) remains the leading cause of premature morbidity and mortality in individuals with type 1 diabetes mellitus (T1DM), despite advances in glycemic management and cardiovascular prevention. Conventional cardiovascular risk assessment may underestimate risk in T1DM, particularly among younger asymptomatic individuals, highlighting the need for markers of early vascular injury. Diabetic retinopathy (DR), a… Continue reading Retinal and coronary imaging in type 1 diabetes: links between retinopathy and subclinical cardiovascular disease
Category: Cardiology
Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality
BACKGROUND Cardiovascular-kidney-metabolic (CKM) syndrome reframes cardio-renal-metabolic risk but omits hepatic dysfunction, particularly metabolic dysfunction-associated fatty liver disease (MAFLD). This study assesses whether integrating MAFLD into the CKM framework improves mortality risk discrimination compared with the original CKM framework. MATERIAL AND METHODS We used data of 10 335 adults aged 20 to 74 years from the… Continue reading Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality
Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atherosclerotic cardiovascular disease and calcific aortic valve disease. In contrast, associations with other cardiovascular phenotypes are less consistent. Since circulating concentrations… Continue reading Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
Effects of warm water footbath on sleep quality and fatigue in patients with heart failure: a randomized controlled study Introduction: Poor sleep quality and fatigue are common and clinically important problems in patients with heart failure (HF). Warm water footbaths are a form of local heat therapy that can induce comfort, relieve fatigue, and improve… Continue reading
Antithrombotic Therapy in Patients with Chronic Coronary Disease on Anticoagulation: Evidence from Contemporary Trials
Introduction: Chronic coronary disease (CCD) commonly coexists with long-term oral anticoagulation (OAC), particularly for atrial fibrillation (AF). Combination antiplatelet therapy increases bleeding, whereas ischemic protection with OAC alone remains a concern. We critically appraised contemporary evidence and guidelines to define optimal long-term maintenance therapy.Methods: We synthesized WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, AFIRE, OAC-ALONE, PRAEDO-AF,… Continue reading Antithrombotic Therapy in Patients with Chronic Coronary Disease on Anticoagulation: Evidence from Contemporary Trials
Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement
Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular-kidney-metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently coexist and interact through shared pathophysiological mechanisms that promote HF onset, especially with preserved ejection fraction… Continue reading Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement
Lipid Metabolism, Statins and Bleeding Risk During Anticoagulant Therapy: Emerging Pharmacological Insights
Lipid metabolism, coagulation, inflammation, and vascular integrity are closely interconnected biological systems. Although statins are primarily prescribed to reduce low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease, increasing evidence indicates that these agents exert multiple pharmacological effects beyond lipid lowering, including modulation of endothelial function, platelet activation, tissue factor expression, thrombin generation, fibrinolysis, and… Continue reading Lipid Metabolism, Statins and Bleeding Risk During Anticoagulant Therapy: Emerging Pharmacological Insights
Is Ferroptosis and Oxidative Stress Involved in NSTEMI Patient’s?
Highlights: Ferroptosis (iron-dependent lipid peroxidation-driven cell death) is implicated in ischemic injury.NSTEMI patients showed significantly higher oxidative stress (↑LPO) and iron overload (↑iron, ↑ferritin) vs controls.Antioxidant defenses were reduced in NSTEMI (↓TAC, ↓TTG, ↓SOD, ↓GPx activity).This biomarker pattern supports ferroptosis activation contributing to myocardial injury in NSTEMI.Background: Ischemic heart disease is the leading cause of… Continue reading Is Ferroptosis and Oxidative Stress Involved in NSTEMI Patient’s?
Clinical Vulnerability Refines Rhythm-Related Outcomes in Older Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation: An Observational Cohort Study
Introduction: Chronological age is often considered when selecting patients for atrial fibrillation (AF) ablation, but age alone may not identify which older patients are most likely to require recurrent rhythm-related care after pulmonary vein isolation (PVI).Methods: We conducted a single-center observational study of consecutive patients undergoing PVI. The principal registry cohort assessed the same-center recurrence-related… Continue reading Clinical Vulnerability Refines Rhythm-Related Outcomes in Older Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation: An Observational Cohort Study
